An-Fang Huang

Dr. An-Fang Huang

Department of Rheumatology and Immunology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ZYZhi-Chao Yuan
Zhi-Chao Yuan
WXWang-Dong Xu
Wang-Dong Xu
XLXiao-Yan Liu
Xiao-Yan Liu
XLXing-You Liu
Xing-You Liu
AHAn-Fang Huang
An-Fang Huang
LSLin-Chong Su
Lin-Chong Su
Interleukin (IL)-36 is a member of the IL-1 superfamily and includes three agonists (IL-36α, IL-36β, and IL-36γ) and an antagonist (IL-36Ra). IL-36 agonists bind to heterodimeric receptor complexes. Then, the heterotrimer complexes signal via intracellular functional domains, binding to downstream signaling proteins and inducing inflammatory responses. In this review, we summarized the current knowledge about the biological role of IL-36 and its correlation with systemic inflammatory diseases. The information collected will help to increase the understanding of the potential of IL-36 and may give clues for developing novel therapeutic strategies.

1 July 2018 in Autoimmunity Reviews
Verified
Journal Article
Closed access
LSLin-Chong Su
Lin-Chong Su
XLXiao-Yan Liu
Xiao-Yan Liu
AHAn-Fang Huang
An-Fang Huang
WXWang-Dong Xu
Wang-Dong Xu

1 March 2020 in Autoimmunity Reviews
Verified
Journal Article
Closed access
LSLin-Chong Su
Lin-Chong Su
WXWang-Dong Xu
Wang-Dong Xu
AHAn-Fang Huang
An-Fang Huang

14 July 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
WXWang-Dong Xu
Wang-Dong Xu
RLRong Li
Rong Li
AHAn-Fang Huang
An-Fang Huang
TL1A, also called TNFSF15, is a member of tumor necrosis factor family. It is expressed in different immune cell, such as monocyte, macrophage, dendritic cell, T cell and non-immune cell, for example, synovial fibroblast, endothelial cell. TL1A competitively binds to death receptor 3 or decoy receptor 3, providing stimulatory signal for downstream signaling pathways, and then regulates proliferation, activation, apoptosis of and cytokine, chemokine production in effector cells. Recent findings showed that TL1A was abnormally expressed in autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, primary biliary cirrhosis, systemic lupus erythematosus and ankylosing spondylitis. In vivo and in vitro studies further demonstrated that TL1A was involved in development and pathogenesis of these diseases. In this study, we comprehensively discussed the complex immunological function of TL1A and focused on recent findings of the pleiotropic activity conducted by TL1A in inflammatory autoimmune disease. Finish of the study will provide new ideas for developing therapeutic strategies for these diseases by targeting TL1A.

22 June 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
WXWang-Dong Xu
Wang-Dong Xu
AHAn-Fang Huang
An-Fang Huang
Interleukin (IL)-38 is the newest member of the IL-1 family. It can bind to several receptors, regulate the generation, function of inflammatory cytokines through the downstream signaling pathways. IL-38 is expressed in several tissues, such as placenta, heart, and brain. It is involved in a wide variety of diseases, including chronic inflammatory diseases. In this review, we discuss the expression and biological functions of IL-38, especially the role in rheumatic autoimmune diseases. Collection of the information may improve the understanding of IL-38, and may give potential for theoretical basis for clinical trials and drug development in the future.

8 January 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JWJia-Min Wang
Jia-Min Wang
WXWang-Dong Xu
Wang-Dong Xu
ZYZhi-Chao Yuan
Zhi-Chao Yuan
QWQian Wu
Qian Wu
JZJie Zhou
Jie Zhou
AHAn-Fang Huang
An-Fang Huang
This study aimed to discuss association between serum Angiopoietin2 (Ang2) levels, Ang2 gene polymorphisms and systemic lupus erythematosus (SLE) susceptibility. It was carried out by 235 SLE, 342 other inflammatory autoimmune diseases patients and 380 healthy individuals. Serum Ang2 levels was examinated by ELISA, and Ang2 rs12674822, rs1823375, rs1868554, rs2442598, rs3739390 and rs734701 polymorphisms were genotyped using KASP. Increased Ang2 concentrations in SLE patients were observed compared with healthy controls and patients with other inflammatory autoimmune diseases. For allelic contrast, except for rs1823375 (P = 0.058) and rs2442598 (P = 0.523), frequencies of alleles for other polymorphisms were significantly different between SLE patients and controls. Genotypes for rs12674822 (TT), rs1868554 (TT, TA and TT+TA), rs734701 (TT) were negatively correlated with SLE susceptibility (OR = 0.564 for rs12674822; OR = 0.572, OR = 0.625, OR = 0.607 for rs1868554; OR = 0.580 for rs734701). Patients carrying rs1868554 T allele and rs3739390 G allele were more likely to develop hematuria (P = 0.039; P = 0.003). The G allele frequencies of rs12674822 and rs2442598 were higher in SLE patients with proteinuria (P = 0.043; P = 0.043). GC genotype frequency of rs3739390 was higher in patients with ds-DNA (+) (P = 0.024). In summary, SLE had increased serum Ang2, which may be a potential biomarker, and the polymorphisms correlated with SLE.